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Abstract 
The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization 
workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept 
of multi‑morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used glob‑
ally for all countries and populations. ARIA—disseminated and implemented in over 70 countries globally—is now 
focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA 
(Contre les Maladies Chroniques pour un Vieillissement Actif)‑ARIA Sentinel NetworK] uses mobile technology to develop 
care pathways for the management of rhinitis and asthma by a multi‑disciplinary group and by patients themselves. 
An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symp‑
tom control and work productivity as well as a clinical decision support system. It is associated with an inter‑operable 
tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the 
European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an 
active and healthy life to rhinitis sufferers, whatever their age, sex or socio‑economic status, in order to reduce health 
and social inequalities incurred by the disease.
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Background
The Allergic Rhinitis and its Impact on Asthma (ARIA) 
initiative commenced during a World Health Organiza-
tion (WHO) workshop in 1999 (published in 2001) [1]. 
The goals were (1) to propose a new allergic rhinitis (AR) 
classification using persistence and severity of symp-
toms in order to more closely reflect patients’ needs, (2) 
to promote the concept of multi-morbidity in asthma 
and rhinitis as a key factor for patient management, (3) 
to develop guidelines with all stakeholders, (4) to include 
experts from developed and developing countries and (5) 
to initiate global implementation among health care pro-
fessionals (HCPs) and patients.
Patients, clinicians and other HCPs are confronted 
with various treatment choices for the management of 
AR. This contributes to considerable variation in clinical 
practice. Worldwide, patients, clinicians and other HCPs 
are faced with uncertainty about the relative merits and 
downsides of the many AR treatment options available. 
The first ARIA workshop report used the Shekelle evi-
dence-based methodology [1, 2]. It was the first guideline 
in chronic disease to assess multi-morbid conditions (i.e. 
asthma and rhinitis in the same patient). In 2008, ARIA 
was updated using the same evidence-based system [3]. 
More transparent reporting of guidelines to facilitate 
understanding and acceptance was needed. In its 2010 
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Revision, ARIA was the first chronic respiratory dis-
ease guideline to adopt the GRADE (Grading of Recom-
mendation, Assessment, Development and Evaluation) 
approach, an advanced evidence evaluation methodology 
[4–7]. A new revision is pending.
ARIA has been disseminated and is implemented in 
over 70 countries around the world [8]. It is now focusing 
on the implementation of emerging technologies for indi-
vidualized and predictive medicine. MASK [MACVIA 
(Contre les Maladies Chroniques pour un Vieillissement 
Actif)-ARIA Sentinel NetworK] uses mobile technology 
to develop care pathways for the management of rhinitis 
and asthma by a multi-disciplinary group and by patients 
themselves [9].
The aim of the novel ARIA approach is to provide an 
active and healthy life to rhinitis sufferers, whatever their 
age, sex or socio-economic status in order to reduce 
health and social inequalities incurred by the disease.
AIRWAYS ICPs: the ARIA 2016 political agenda
In 2012, the European Commission launched the Euro-
pean Innovation Partnership on Active and Healthy 
Ageing (EIP on AHA; DG Santé and DG CONNECT) 
to enhance EU competitiveness and tackle societal chal-
lenges through research and innovation [10]. The B3 
Action Plan is devoted to the scaling up and replica-
tion of successful innovative integrated care models for 
chronic diseases amongst older patients.
Chronic respiratory diseases were selected to be the 
pilot for chronic diseases of the EIP on AHA Action Plan 
B3 (Integrated care pathways for airway diseases, AIR-
WAYS ICPs) [11, 12] with a life cycle approach [13]. Sev-
eral effective plans exist in Europe for chronic respiratory 
diseases, but they are rarely deployed to other regions or 
countries.
AIRWAYS ICPs aims to launch a collaboration to 
develop practical multi-sectoral care pathways (i.e. ICPs) 
in European countries and regions to reduce chronic res-
piratory disease burden, mortality and multi-morbidity, 
while maintaining patients’ quality-of-life (QOL) [11, 14]. 
AIRWAYS-ICPs proposes a feasible, achievable and man-
ageable project (from science to guidelines and policies) 
using existing networks. It brings together key stakehold-
ers including end users, public authorities, industry part-
ners, involved in the innovation cycle, from research to 
adoption, as well as those engaged in standardisation and 
regulation. The Action Plan of AIRWAYS ICPs has been 
devised [11], implemented [14] and scaled up [15].
AIRWAYS ICPs is a GARD (WHO Global Alliance 
against Chronic Respiratory Diseases) [16] research dem-
onstration project. Its deployment beyond Europe is car-
ried out via GARD.
One AIRWAYS-ICPs activity is the development of 
multi-sectoral care pathways for rhinitis and asthma and 
their multi-morbidities, implementing emerging technol-
ogies for predictive medicine across the patient life cycle 
[13].
From guidelines to integrated care pathways: 
MACVIA‑ARIA Sentinel NetworK (MASK)
Best practice, guideline and care pathways
A good or best practice is a technique, method, process, 
activity, incentive, or reward believed to be more effective 
than any other technique, method, process, etc. when 
applied to a particular condition or circumstance. A best 
practice can be adopted as a standard process or be used 
as a guideline (U.S. Dept. of Veterans Affairs [17]).
A guideline is a statement to determine a course of 
action. It aims to streamline particular processes accord-
ing to a set routine or sound practice. By definition, fol-
lowing a guideline is never mandatory. Guidelines are 
not binding and are not enforced (U.S. Dept. of Veterans 
Affairs [17]).
“Clinical practice guidelines are systematically devel-
oped statements to assist practitioner and patient deci-
sions about appropriate health care for specific clinical 
circumstances” (Institute of Medicine, 1990). These clini-
cal practice guidelines define the role of specific diag-
nostic and treatment modalities. The statements include 
recommendations based on evidence intended to help 
HCPs and providers in their practice [18].
The Integrated Care Pathway (ICP) concept was initi-
ated in 1985 by Zander and Bower [19]. ICPs are struc-
tured multi-disciplinary care plans detailing key steps of 
patient care for a given clinical problem [20]. They pro-
mote the translation of guidelines into local protocols 
and their subsequent application to clinical practice. An 
ICP forms all or part of the clinical record, documents 
the care given, and facilitates the evaluation of out-
comes for continuous quality improvement [21]. They 
can help empower patients and their carers (health and 
social). ICPs differ from clinical practice guidelines as 
they are utilized by a multi-disciplinary team, and focus 
on the quality and co-ordination of care. ICPs need to 
have a mechanism for recording variations/deviations 
from planned care. Like guidelines, an ICP is a guide to 
treatment, and clinicians are free to exercise their own 
professional judgment as appropriate. However, any 
alteration to the practice identified within this ICP must 
be noted as a variance [22]. Variance analysis is a criti-
cal part of developing and using ICPs [23]. The resulting 
analysis can be used to amend the ICP itself if, for the 
majority of patients, the practice is different to the path-
way (Table 1).
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Multisectoral care pathways for rhinitis and asthma using 
ICT
A large number of AR patients do not consult physi-
cians because they think their AR symptoms are ‘normal’ 
and/or trivial. However, AR negatively impacts social 
life, school and work productivity [3]. Many AR patients 
use over the counter (OTC) drugs [24] and only a frac-
tion have had a medical consultation. The vast majority 
of patients who visit GPs or specialists have moderate/
severe rhinitis [25–29]. Thus, ICPs should consider a 
multi-disciplinary approach as proposed by AIRWAYS 
ICPs (Fig. 1).
The variations/deviations of the ARIA recommenda-
tions from planned care have been assessed and several 
unmet needs identified. Disease severity is associated 
with several health outcomes, including quality of life 
[25–29], and should be considered in ICPs. The dura-
tion of rhinitis (intermittent/severe-persistent) is an 
important indicator of asthma multi-morbidity (in some 
but not all studies) [30], duration of AR treatment and 
efficacy of treatment in AR [27]. Most patients receive 
combinations of oral antihistamines and intra-nasal cor-
ticosteroids (INS) [31–33] which are not evaluated in 
guidelines using an appropriate methodology.
Simple approach to assess control in allergic rhinitis
In asthma, the management strategy is based on disease 
control, current treatment and future risk (exacerbations, 
lung function decline) [34–36]. In AR, the switch from 
symptom severity to disease control to guide treatment 
decisions has been led by ARIA and is now expanding to 
include MACVIA (a reference site of the EIP on AHA, 
EU [37]) to form an Action Plan (MACVIA-ARIA). New 
developments which have facilitated this process include 
(1) the introduction of the visual analogue scale (VAS) as 
the common validated language of AR control, (2) cat-
egorization of AR control using VAS score cut-offs, (3) 
incorporation of this VAS into simple interactive apps 
for both patients (ARIA Allergy Diary) and HCPs (ARIA 
Allergy Diary Companion) [9, 38] and (4) the integration 
of all this knowledge into ICPs deployed by the EIP on 
AHA [9].
The VAS represents a simple way of measuring con-
trol. It has been used in many diseases, including AR. 
VAS scores appear to be similar in different countries, for 
patients with moderate–severe intermittent or persistent 
rhinitis [39, 40]. An advantage of the VAS is that it can 
be used in all age groups, including preschool children 
(guardian evaluation) [41] and the elderly [42, 43]. Fur-
thermore, it can be used in a wide variety of languages 
[39, 40, 42, 44–48]. VAS scores vary with ARIA AR clas-
sification in many languages [28, 44, 49, 50]. A VAS score 
of 50/100  mm suggests moderate–severe AR [32, 51, 
52], although in some studies this cut-off was >60  mm 
[45]. The VAS has been used to define severe chronic 
upper airway disease (SCUAD [53]). The minimal clini-
cally important difference (MCID) during treatment was 
found to be 2.3/10 cm in the French population [54] and 
may be generalized to other countries, but future studies 
may refine this cut-off score. VAS score changes appear 
to encompass both symptoms and disease-specific QOL 
[54, 55].
As is the case for asthma, the best control of AR should 
be achieved as early as possible in order to (1) improve 
patient satisfaction and concordance with treatment and 
(2) reduce the AR burden including symptoms, reduced 
QoL, and school and work presenteeism/absenteeism. 
Untreated AR can impair driving ability and put patients 
at risk [56]. The ultimate goal of AR control is to reduce 
the direct and indirect costs incurred by AR [57–60].
The variability in approaches to achieve disease control 
is challenging, and necessitates careful monitoring as well 
as the step up/step down of individualized therapeutic 
regimens over time. However, the challenges of managing 
AR are increased by the fact that patients do not often 
recognise their AR symptoms or confuse them with those 
of asthma or other multimorbidities such as rhinosinusi-
tis [61]. Therefore, it is important for patients, caregivers 
or HCPs to be able to use an AR symptom scoring system 
that is simple to use and rapidly responsive to change.
The aim is to encourage effective cross communica-
tion and achieve rapid and sustained disease control. 
MACVIA-ARIA has produced a simple VAS-based algo-
rithm called the ARIA Clinical Decision Support System 
(CDSS) using a VAS score to guide treatment decisions 
in a step-up/step-down approach. This CDSS provides 
an individualized approach to AR pharmacotherapy 
(depending on medication availability and resources) 
[62]. This approach holds the potential for optimal AR 
control while minimizing side effects and costs.
MASK (MACVIA‑ARIA Sentinel NetworK): rhinitis 
and asthma
MASK-rhinitis and asthma is a simple ICT tool used to 
implement ICPs for AR and asthma by means of a com-
mon language (for patients and HCPs) and a CDSS. 
Disease control is assessed by VAS, incorporated into 
apps for patients (ARIA Allergy Diary) and HCPs (ARIA 
Allergy Diary Companion), with the utility to assess 
patient QoL (weekly EQ-5D) [63, 64] and school/work 
productivity (weekly WPAI-AS and daily VAS) [25, 65, 
66].
MASK-rhinitis and asthma will (1) allow patients and 
caregivers to screen for AR and asthma, and track their 
AR control (2) guide pharmacists in the prescription of 
OTC medications and referral of patients to physicians 
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when appropriate, (3) allow primary care physicians to 
prescribe appropriate AR treatment, assess patients’ AR 
control and direct follow-ups in accordance with the 
CDSS and (4) encourage referral to specialists and out-
patient clinics, if there is failure to gain AR control at the 
primary care level.
MASK-rhinitis and asthma will be important for estab-
lishing care pathways across the life cycle. It will stratify 
patients with severe uncontrolled disease and achieve 
better results in prevention and intervention trials guided 
by the use of an individualised and predictive medicine 
approach.
The MASK tools: the ARIA Allergy Diary and ARIA Allergy 
Diary Companion apps
The ARIA Allergy Diary is freely available in 15 EU 
countries, Australia, Mexico and Switzerland and in 15 
languages (translated and back-translated, culturally 
adapted and legally compliant). It will also be deployed in 
Brazil, Canada and the USA. The companion app will be 
available in Autumn 2016.
A pilot study was completed in AR during the pol-
len season to assess the relevance of the ARIA Allergy 
Diary app. It showed the importance of the tool to strat-
ify patients, assess their work productivity and improve 
quality of life (EQ-5D) (Bousquet et al., submitted). Stud-
ies in asthma are planned for the autumn and winter.
Questionnaires
ARIA Allergy Diary users fill in simple questionnaires 
on asthma, rhinitis and the impact of the disease (glob-
ally, on work and school, on daily activities and on sleep) 
upon registration (Table  2). The pilot study in around 
5000 users (9% over 60 years of age) indicates that these 
questions are easily answered and can help to stratify 
patients with rhinitis.
Moreover, two specific questionnaires are applied every 
week to assess disease impact on patients’ QoL (EQ-5D) 
[63, 64] and productivity at work (WPAI-AS) [25, 65, 66].
Treatments received
A list of all treatments available for asthma, conjuncti-
vitis and rhinitis is included in the ARIA Allergy Diary, 
and users select the treatment(s) they are taking. Multi-
ple treatments may be selected, and users can update the 
information when (or if ) their treatment changes (Fig. 2). 
The list has been customized for all 20 countries in which 
the ARIA Allergy Diary is available, using data from IMS 
Health. Information on allergen specific immunotherapy 
is also requested on the day of first use. A questionnaire 
on biologics for asthma is under development.
Daily visual analogue scales
Geolocalized users assess their daily symptom control 
using the touchscreen functionality on their smart phone 
to click on 5 consecutive VASs (global symptoms due to 
allergic diseases, rhinitis, conjunctivitis, asthma and work 
productivity) (Fig.  3). These scales have been validated 
for AR and asthma criteria [67–71] and for work produc-
tivity (Bousquet et al., in preparation).
MASK‑asthma
Besides the asthma VAS, a test to measure pulmonary 
function is being developed. It is expected to be added to 
the ARIA Allergy Diary by the end of 2016.
Clinical decision support system
The MASK CDSS is incorporated into an app for HCPs 
(i.e. ARIA Allergy Diary Companion). This is essentially 
an algorithm to aid clinicians to select pharmacotherapy 
for patients with AR and to stratify their disease sever-
ity [62]. It uses a simple step-up/step-down individual-
ized approach to AR pharmacotherapy and may hold 
the potential for optimal control of symptoms, while 
minimizing side effects and costs. However, its use varies 
depending on the availability of medications in the dif-
ferent countries and on resources. A CDSS for asthma is 
also being developed.
Ethics
The terms of use have been translated into all languages 
and customized according to the country’s legislation. 
They allow the use of anonymous data for research and 
commercial purposes. The app has a CE registration as a 
medical device class 1.
Patient empowerment
The validation of the ARIA Allergy Diary has already 
been accomplished (manuscript in preparation). With 
Fig. 1 Multi‑sectoral care pathway for allergic rhinitis (from Bousquet 
et al. [9])
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the help of patient organisations (EFA: European Federa-
tion of Allergy and Airways Diseases Patients’ Associa-
tions), it will be evaluated and improved by the patients 
themselves.
New concepts in allergic multimorbidity embedded 
in ARIA
The term allergic multimorbidity is more appropriate 
than comorbidity since the primary allergic disease is 
poorly known [72].
Stratification of severe allergic and/or asthma patients
Despite the major advances in understanding aller-
gic diseases or asthma, treatments are not effective in 
all patients. From a clinical perspective, implementing 
knowledge-based decisions on what therapeutics to use 
for which patients and, if relevant, in which combina-
tions, is extremely challenging. The aspiration to pro-
vide more effective therapeutic interventions tailored 
to the individual remains unfulfilled because of the 
variable response of individuals to such interventions. 
Patient stratification aims at grouping patients into dis-
ease sub-groups, where the specific pathological pro-
cesses involved are better defined (clinical/molecular 
phenotypes).
Long-term birth cohort studies are essential for under-
standing the life course, early predictors, risk and pro-
tective factors of allergic diseases (including asthma and 
rhinitis) and the complex interplay between genes and 
environment (including life style and socio-economic 
determinants) [73]. MeDALL (Mechanisms of the Devel-
opment of ALLergy; EU FP7-CP-IP; Project No.: 261357; 
2010–2015) attempted to better understand the complex 
links of allergic diseases at the clinical and mechanistic 
levels [74–76].
MeDALL identified a rare but severe allergy phenotype: 
polysensitized-multimorbid phenotype. Although mul-
timorbidity is not always associated with allergy, stud-
ies in MeDALL [77] on children, in the PARIS cohort at 
2 years of age [78], in EGEA on adults [79, 80] (Siroux, in 
preparation) and patient cohorts in subjects with peanut 
allergy [81] all show that subjects who are polysensitized 
and multimorbid have a very high frequency of allergic 
symptoms, persistent symptoms over time, more severe 
asthma symptoms than other phenotypes and higher 
total and specific IgE levels.
Taken altogether, these results indicate that asthmatic 
patients cannot be managed appropriately without 
assessing rhinitis multimorbidity and also reinforce the 
importance of nasal problems (rhinitis and/or rhinosi-
nusitis) in many uncontrolled asthmatic patients [82–84].
Allergic multimorbidity in old age adults
Asthma and rhinitis often start in early age and persist in 
most, but not all, subjects. The expected epidemic wave 
of asthma and rhinitis in older adults is an insufficiently 
recognized problem. In Europe, over 20% of adults suf-
fer from AR and over 5% from asthma. These patients 
are now reaching the age of 65  years and a new health 
problem in older adults will be to understand, detect 
and manage these patients. Asthma and rhinitis in older 
adults have specific symptoms and treatment needs, 
which are different from those in younger adults. These 
patients also suffer from multi-morbididy with high rates 
of poly-pharmacy reported. Integrated Care Pathways 
(ICPs) for rhinitis and asthma should cover the entire life 
cycle.
Table 2 Baseline questionnaire
Q1: I have rhinitis: yes/no
Q2: I have asthma: yes/no
Q3: My symptoms (tick)
 Runny nose
 Itchy nose
 Sneezing
 Congestion (blocked nose)
 Red eyes
 Itchy eyes
 Watery eyes
Q4: How they affect me: my symptoms (tick)
 Affect my sleep
 Restrict my daily activities
 Restrict my participation in school or work
 Are troublesome
Q5: Medications
Q6: Are you currently receiving immunotherapy (a small dose of the 
thing you are allergic to, usually taken as an injection or placed under 
your tongue)? yes/no
 If YES to Q6 (Q7 and Q8)
Q7: What allergy is this?
 Grass pollen
 Parietaria pollen
 Birch pollen
 Other pollen
 Dust mite
 Animal
 Cypress tree pollen
 Don’t know
 Add allergy
Q8: How do you receive your treatment?
 Injection
 Tablet under the tongue
 Drops under the tongue
 Spray under the tongue
 Other
Page 8 of 14Bousquet et al. Clin Transl Allergy  (2016) 6:47 
The scaling up strategy
The EIP on AHA has proposed a 5-step framework for 
developing an individual scaling up strategy: (1) what to 
scale up: (1-a) databases of good practices, (1-b) assess-
ment of viability of the scaling up of good practices, (1-c) 
classification of good practices for local replication and 
(2) how to scale up: (2-a) facilitating partnerships for 
scaling up, (2-b) implementation of key success factors 
and lessons learnt, including emerging technologies for 
individualised and predictive medicine. This strategy has 
Fig. 2 Screens on medications
Fig. 3 Screens on daily visual analogue scales
Page 9 of 14Bousquet et al. Clin Transl Allergy  (2016) 6:47 
already been applied to the chronic respiratory diseases 
action plan of the EIP on AHA [15].
There is an urgent need for scaling up strategies in 
order to (1) avoid fragmentation, (2) improve health care 
delivery across Europe, (3) speed up the implementation 
of good practices using existing cost-effective success sto-
ries and (4) meet the EIP on AHA objectives [10].
Reference Site Collaborate Network (RSCN) of the EIP 
on AHA
The RSCN brings together all EIP on AHA Reference 
Sites, and Candidate Reference Sites, across Europe into 
a single forum. The aim is to promote cooperation and 
develop and promote areas of innovative good prac-
tice and solutions, which contribute to improved health 
and care outcomes for citizens across Europe. The hope 
is to develop sustainable economic growth and create 
jobs. Members of 13 EIP on AHA Reference Sites (2013) 
have agreed on the AIRWAYS ICPs concept and are co-
authors of the paper published in Clinical Translational 
Allergy [15]. A meeting of all EIP on AHA Reference 
Sites was co-organised by the Région LR, North Eng-
land [85] and the EIP on AHA Reference Site Collabora-
tive Network to scale up AIRWAYS ICPs in all Reference 
Sites (October 21, 2014). 74 EIP on AHA Reference Sites 
have now been approved by the EU (2016). A Twinning 
project has also been approved by the EIP on AHA to 
deploy MASK in 13 Reference Sites in order to compare 
allergic rhinitis diagnoses by allergists in adults and older 
people to study phenotypes, treatments and care path-
ways of rhinitis.
Conclusion
 ARIA has evolved from a rigorously developed guideline 
to a mobile technology-based implementation strategy 
in order to provide an active and healthy life to rhinitis 
sufferers, whatever their age, sex or socio-economic sta-
tus with the aim to reduce health and social inequalities 
incurred by this very common disease globally.
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